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vaccination (UMV) program with a 2 þ 1 schedule of a 10-valent
pneumococcal polysaccharide nontypeable Haemophilus inﬂuenzae pro-
tein D conjugate vaccine (PHiD-CV) against two strategies: 1) a no-
vaccination strategy and 2) a pneumococcal 13-valent conjugate
vaccine (PCV13) 2 þ 1 strategy in the Philippines. Methods:
A published Markov cohort model was adapted to simulate the
epidemiological and economic burden of pneumococcal diseases
(meningitis, bacteremia, pneumonia, and acute otitis media) within
a projected birth cohort in 2012 of 1,812,137 newborns over lifetime.
Analyses were conducted at an annual discount rate of 5% from the
perspective of the Philippine government. The current evaluation was
updated with the best available local/regional clinical epidemiological
data and published efﬁcacy evidence. Results: Compared with the no-
vaccination strategy, the PHiD-CV 2 þ 1 UMV program was projected
to prevent 3,343 deaths due to invasive pneumococcal diseases and2014, International Society for Pharmacoeconomic
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Open access under CC BY-NC-ND license.pneumonia and 326,862 cases of pneumococcal diseases, resulting in
an incremental cost-effectiveness ratio of 50,913 pesos/quality-
adjusted life-year gained, which was considered to be highly cost-
effective according to the threshold recommended by the World
Health Organization. In comparison with the PCV13 2 þ 1 strategy,
the PHiD-CV 2 þ 1 strategy was estimated to have a substantial
reduction in acute otitis media (127,680 cases) and therefore a cost
saving of potential 92.5 million pesos assuming price parity between
PHiD-CV and PCV13 (US $1 ¼ 42.13 pesos in 2012). Conclusions: The
PHiD-CV 2 þ 1 UMV program is projected to be cost-effective,
compared with no vaccination, and would provide substantial savings
with higher quality-adjusted life-year gains as compared with the
PCV13 2 þ 1 strategy in the context of the Philippines.
Keywords: cost-effectiveness, PCV13, PHiD-CV, Philippines, vaccination.
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The World Health Organization (WHO) estimated that 1.6 million
people die every year from invasive pneumococcal diseases
(IPDs), and an estimated 0.7 to 1 million of these are children
younger than 5 years [1]. A study conducted in the Philippines
showed that the peak incidence of IPDs is in children younger
than 4 years. The same study estimated that one third of the
children younger than 5 years with IPD would die [2].
Acute otitis media (AOM) is also a signiﬁcant, although largely
underestimated, public health burden among Filipino children.
There is a paucity of good surveillance data regarding the extent
of the burden of otitis media (OM) and/or AOM in Filipino
children. A local study indicated that up to 25% of the childrenwith pneumonia had concomitant OM [3]. In a recent national
survey, the overall prevalence of clinically diagnosed AOM in
children aged 0 to 12 years in the Philippines was estimated at
9.57%, with the 0 to 2 years age group having the most prevalent
cases of AOM in the sample [4]. This prevalence rate is considered
as high on the basis of the WHO classiﬁcation for the prevalence
of OM [5].
At present, two types of pneumococcal conjugate vaccines are
available for use in children in the Philippines market. These are
SynﬂorixTM (GlaxoSmithKline, Rixensart, Belgium), a pneumococcal
polysaccharide and nontypeable Haemophilus inﬂuenzae protein D
conjugate vaccine (PHiD-CV) and Prevnar 13TM (Wyeth LLC, Madi-
son, NJ, now part of Pﬁzer, Inc.), a pneumococcal 13-valent con-
jugate vaccine (PCV13). Both vaccines are licensed locally as a 2 þ 1s and Outcomes Research (ISPOR).
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and children aged 6 weeks to 5 years against disease caused by
Streptococcus pneumoniae (including meningitis, sepsis, bacteremia,
pneumonia, and AOM) [6,7]. In addition, PHiD-CV is also licensed for
use against OM caused by nontypeable Haemophilus inﬂuenzae (NTHi)
and licensed for use in preterm infants [6].
Health economics has been increasingly incorporated into the
comprehensive health technology assessment for formulary and
vaccine policy decision making over the past decade. Published
results from other countries might not be directly transferable
because of the sensitivity of key local data inputs such as
epidemiology, local treatment patterns, or prices [8].
The purpose of this study was to evaluate the epidemiological
and economic consequences of pneumococcal conjugate vacc-
ine(s) for a universal mass vaccination (UMV) program in addition
to the current standard of care for pneumococcal diseases in
the Philippines in 2012, using an adapted Markov cohort model.
The two analyses presented in this article compared the
cost-effectiveness of a UMV program with PHiD-CV 2 þ 1
versus no vaccination, and that of PHiD-CV 2 þ 1 versus PCV13, in
the Philippines. The samemodel has been adapted for analyses in a
number of different countries such as Norway and Sweden [9,10].Methods
Markov Cohort Model
A published Markov cohort model was adapted to simulate the
epidemiological burden of pneumococcal and NTHi-related dis-
eases, including IPDs, community-acquired pneumonia (CAP),
and AOM, within a projected registered live birth cohort of
1,812,137 newborns in the Philippines in 2012 [11,12]. Cohort-
based analyses represent one of the most common forms ofFig. 1 – Markov cohort model design. The cohort model is Mark
sequelae, and death. The transition from “no disease” to “sequel
In the model, only meningitis can lead to long-term sequelae; m
bacteremia, respectively; and nonconsulting AOM are accounted
media; GP, general practitioner; NTHi, nontypeable Haemophilus inﬂ
valent conjugate vaccine; PHiD-CV, pneumococcal polysaccharide nhealth economic modeling and are particularly useful for deter-
mining the direct effect of medical interventions [13].
In the Markov cohort model, the individuals of the birth
cohort move between the Markov states, as shown in Figure. 1,
according to estimated transition probabilities derived from the
published incidence rates, over a projection of lifetime horizon.
The model has a number of mutually exclusive disease-related
outcomes, including meningitis, bacteremia, CAP, AOM, no pneu-
mococcal infection, and death. Costs and quality-adjusted life-
year (QALY) speciﬁc to each health state were estimated and
summarized over the cohort’s lifetime to calculate total accumu-
lated costs and QALYs. The incremental cost and QALY gained of
the two different strategies were computed as an incremental
cost-effectiveness ratio (ICER) for each set of comparison (PHiD-CV
vs. no vaccination; PHiD-CV vs. PCV13). The WHO-recommended
thresholds for ICER were adopted in the study: 1) cost-saving: if the
strategy costs less and provides higher QALYs; 2) cost-effective:
the ICER is below three times the gross domestic product (GDP) per
capita of the country; 3) highly cost-effective: the ICER is below one
time the GDP per capita of the country; and 4) not cost-effective:
the ICER is more than three times the GDP per capita of the
country (GDP per capita of the Philippines in 2011 ¼ 103,366 pesos)
[14]. It was assumed in the base-case scenario that 100% of the
birth cohort would be vaccinated according to the 2 þ 1 schedule
(dose 1 at 6 weeks, dose 2 at 14 weeks, and dose 3 at 13 months).
Finally, it was assumed that there was no herd effect for the UMV
program of both vaccines in the base-case scenario.
Epidemiological Data
The birth cohort size of 2012 used in the analysis was 1,812,137,
which was projected from the 2010 Field Health Service Informa-
tion System report using a 1.9% population growth annually
(National Statistics Ofﬁce, Average population growth rateov-based with three exclusive health states: no disease,
ae” or “death” is calculated on the basis of this decision tree.
eningitis and bacteremia include NTHi meningitis and NTHi
for in the quality-of-life impact calculation. AOM, acute otitis
uenzae; PCP, primary care physician; PCV13, pneumococcal 13-
ontypeable Haemophilus inﬂuenzae protein D conjugate vaccine.
Table 1 – Country-speciﬁc model parameters for the Philippines.
Parameter Philippines value
Size of birth cohort (2012 projected; cohort
model)
1,812,137 [11]
Serotype distribution
Pneumococcal meningitis
1. incidence rate o5 y (per 100,000) 18.3 [2]
2. CFR o5 y (%) 30.8 [2]
3. % cases with long-term sequelae o5 y
(%)
11 [47]
Bacteremia
1. Incidence rate o5 y (per 100,000) 14.06 (r1 y); 7.03 (2–4 y) [2]
2. CFR o5 y (%) 33.3 [2]
3. % cases with long-term sequelae o5 y
(%)
10 [47]
All-cause pneumonia
1. Hospitalization rate o5 y (per 100,000) 7957 (o1 y) (Lucero MG, unpublished ARIVAC data, 2012); 5003 (1 year) (Lucero MG,
unpublished ARIVAC data, 2012); 958 (2–4 y) [11,48,49]
6.4 [21]
2. CFR o5 y (%) 8493 (o1 y) (Lucero MG, unpublished ARIVAC data, 2012); 4849 (1 year) (Lucero MG,
unpublished ARIVAC data, 2012); 2424.5 (2–4 y) (extrapolation, Lucero MG, unpublished
ARIVAC data, 2012)
3. GP consultation rate o5 y (per 100,000) 16412 (r1 y); 11745 (2–4 y) [4]
AOM
1. GP consultation rate o5 y (per 100,000) 98 (extrapolation based on expert opinion, 25% of the ﬁgure from the same age
group [20])
2. Total number of myringotomy
procedures (per 100,000)
See Appendix, Figure. 1
Discount rate (for the base-case scenario) 5%
CFR for meningitis Age-speciﬁc data; see Appendix, Table 1
% cases with long-term sequelae of
pneumococcal meningitis
Age-speciﬁc data; see Appendix, Table 1
Incidence of bacteremia Age-speciﬁc data; see Appendix, Table 2
CFR for bacteremia Age-speciﬁc data; see Appendix, Table 2
% cases with long-term sequelae of
bacteremia
Age-speciﬁc data; see Appendix, Table 2
Hospitalization rate for all-cause
pneumonia
Age-speciﬁc data; see Appendix, Table 3
CFR for all-cause pneumonia Age-speciﬁc data; see Appendix, Table 3
GP consultation rate for all-cause
pneumonia
Age-speciﬁc data; see Appendix, Table 3
GP consultation rate for AOM Age-speciﬁc data; see Appendix, Table 4
Myringotomy procedure rate Age-speciﬁc data; see Appendix, Table 4
AOM complication ratio (for sensitivity
analysis)
Age-speciﬁc data; see Appendix, Table 4
Long-term sequelae rate for AOM Age-speciﬁc data; see Appendix, Table 4
Note. See Appendix in Supplemental Materials found at http://dx.doi.org/10.1016/j.vhri.2014.04.004.
AOM, acute otitis media; ARIVAC, Acute Respiratory Infection Vaccine; CFR, case-fatality ratio; GP, general practitioner.
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data and case-fatality ratios for each pneumococcal/NTHi disease
were obtained from the published literature or national data-
bases from the pre-PCV7 period [2,15]. Table 1 and Appendix
Tables 1 to 4 (in Supplemental Materials found at http://dx.doi.
org/10.1016/j.vhri.2014.04.004) present epidemiological data for
IPD, bacteremia and sepsis, all-cause pneumonia, and AOM
[2,4,15–21, Marcelo MJ. Case Series Report on Otogenic Complica-
tions of Chronic Otitis Media. Philippine Children's Medical
Center, unpublished data, 2004]. Local data were used wherever
available. For certain parameters without local data, data from
neighboring country Malaysia with similar developing country
status, similar seasons, and similar epidemiology data were
revalidated by clinical experts and used for extrapolation of local
data if deemed suitable. For the long-term sequelae data ofinvasive diseases, because of the lack of local or regional data,
published data were used for extrapolations.Vaccine Efﬁcacy Parameters
The model assumed the vaccine efﬁcacy to increase with the
increasing number of doses a child would receive, until maximal
efﬁcacy was achieved after the booster dose at month 13. The
duration of protection was assumed to be 10 years for the 2 þ 1
regimen, with the linear waning of efﬁcacy assumed to start at
the age of 2 years. Vaccine efﬁcacy against IPD was calculated as
a sum product using distribution of local serotypes (Appendix
Figure. 1 in Supplemental Materials found at http://dx.doi.org/10.
1016/j.vhri.2014.04.004) and serotype-speciﬁc efﬁcacy of each
vaccine (Appendix Table 5 in Supplemental Materials found at
Table 2 – Vaccine-speciﬁc model parameters.
Parameter PCV13 value PHiD-CV value
Vaccine efﬁcacy against IPD Serotype-speciﬁc efﬁcacies were taken from a
previous study of PCV7 efﬁcacy [22]
Serotype-speciﬁc efﬁcacies were taken from a
previous study of PCV7 efﬁcacy [22]
For serotypes not covered by PCV7, the mean
efﬁcacy of the PCV7 serotypes was used (94.7%).
No efﬁcacy was assumed for serotype 3 [23–29]
(Appendix, Table 5)
For serotypes not covered by PCV7, the mean
efﬁcacy of the PCV7 serotypes was used (94.7%).
The reported rates of cross-protection for
serotypes 6A (76%) and 19A (26%) were also
included [23–29] (Appendix, Table 5)
Vaccine efﬁcacy against all-
cause pneumonia
Vaccine efﬁcacy: reduction in
GP visits (all-cause
pneumonia)
7.3% (assumed to be the same as PHiD-CV, due to
the lack of data)
7.3% [31]
Vaccine efﬁcacy: reduction in
hospitalized all-cause
pneumonia
23.4% (assumed to be the same as PhiD-CV, due to
the lack of data)
23.4% [31]
Vaccine efﬁcacy against AOM
Vaccine efﬁcacy: reduction in
AOM due to S. pneumoniae
vaccine serotypes
57.2% (95% CI 44%–67%) [38] (assumed to be the
same as PCV7, due to the lack of data)
57.6% (95% CI 41.4%–69.3%) [37] (assumed to be the
same as an earlier 11-valent formulation,
supported by data from well-established animal
models)
Serotype replacement for S.
pneumonia nonvaccine
serotypes
33.0% (80.0%, 1.0%) [4,38] 33.0% (80.0%, 1.0%) [38]
Vaccine efﬁcacy: reduction in
AOM caused by NTHi
0 35.3% (95% CI 1.8%–57.4%) [37]
Note. See Appendix in Supplemental Materials found at http://dx.doi.org/10.1016/j.vhri.2014.04.004.
AOM, acute otitis media; CI, conﬁdence interval; GP, general practitioner; IPD, invasive pneumococcal disease; PCV13, pneumococcal 13-valent
conjugate vaccine; PHiD-CV, pneumococcal polysaccharide nontypeable Haemophilus inﬂuenzae protein D conjugate vaccine.
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robust data on serotype-speciﬁc efﬁcacy are the PCV7 results
reported by Whitney et al. [22]. To the best of our knowledge, so
far there is no published meta-analysis comparing the efﬁcacy of
PHiD-CV and PCV13. In addition, despite the fact that PHiD-CV
has been investigated in two large-scale randomized controlled
trials (Clinical Otitis Media & Pneumonia Study and Finnish
Invasive Pneumococcal disease trial), no published randomized
controlled trial data are available for PCV13.
PHiD-CV and PCV13 were assumed to have the same serotype
efﬁcacy as PCV7 for the seven serotypes covered by the latter. For
the additional serotypes covered by PHiD-CV (i.e., serotypes 1, 5,
and 7F) or PCV13 (i.e., serotypes 1, 3, 5, 6A, 7F, and 19A), the
average vaccine efﬁcacy of PCV7 vaccine serotypes (e.g., 94.7%)
was used as the default value (Table 2). Cross-protection for 6A
(76%) and 19A (26%) were assumed on the basis of PCV 7 vaccine
effectiveness data [22]. No efﬁcacy was assumed for serotype 3
contained in PCV13, as demonstrated by conﬂicting and hypo-
responsive results on the effect of IPD in studies from different
countries [23–28], which probably explains a statement made by
the UK Joint Committee on Vaccination and Immunisation that
“PCV13 is effective against most of the additional six serotypes in
PCV13 but not in PCV7. PCV13 appears ineffective against sero-
type 3” [29].
In the absence of PCV13-speciﬁc pneumonia vaccine efﬁcacy
estimates, the Clinical Otitis Media & Pneumonia Study efﬁcacy
estimates of 23.4% for inpatient pneumonia and 7.3% for out-
patient pneumonia for PHiD-CV were used for both PHiD-CV and
PCV13 vaccines [30]. Despite several pneumonia efﬁcacy trials
with vaccine formulations containing 7, 9, 10, and 11 serotypes
[30–36], all the studies gave point efﬁcacy estimates of between20% and 35%, with no indication that vaccines with more
serotypes provided greater protection against pneumonia. Vac-
cine efﬁcacy against AOM was estimated on the basis of efﬁcacy
against pneumococcal vaccine serotypes and nonvaccine sero-
type disease and efﬁcacy against disease caused by NTHi. For
PHiD-CV, the assumptions were based on the data reported in the
Pneumococcal Otitis Efﬁcacy Trial of an earlier 11-valent protein
D-conjugate vaccine formulation in prevention of AOM caused by
both S. pneumoniae and NTHi [37]. The assumptions of vaccine
efﬁcacy against AOM for PCV13 were based on an earlier random-
ized double-blinded, clinical trial for PCV7 [38].
Using the Philippines epidemiology data and vaccine effec-
tiveness data, a maximal effectiveness was calculated for each
vaccine using the following equation (Appendix Table 6 in
Supplemental Materials found at http://dx.doi.org/10.1016/j.vhri.
2014.04.004):
VEmax ¼ VEVT  % of AOM cases due to vaccine serotypes þ
VENVT  % of AOM cases due to nonvaccine serotypes þ VENTHi 
% of AOM cases due to NTHi
The AOM complications ratio and the long-term sequelae
rate were based on unpublished local data from tertiary hospi-
tal. It is important to note that in the base-case scenario, we
have taken a more conservative stand to exclude the AOM
complications and long-term sequelae from the analysis. In
the sensitivity analysis, the AOM complications and long-term
sequelae were included.
Health Outcomes
The current model was designed to estimate the overall impact of
disease by considering QALY loss in both acute and long-term
Table 3 – Disutility weights of pneumococcal diseases.
Short-term Disutility weight Reference/assumptions
Meningitis (inpatient) 0.023 [39], value for meningitis with recovery
Bacteremia (inpatient) 0.008 [39], value for hospitalization
Pneumonia (inpatient) 0.008 Assumed to be the same as for inpatient bacteremia
Pneumonia (outpatient) 0.006 [39], value for local infection
AOM (outpatient) 0.005 [40]
AOM hospitalized myringotomy 0.005 Assumed to be the same as for AOM
Long-term Disutility weight Reference
Neurological sequelae from meningitis 0.400 [41]
Hearing loss from meningitis 0.200 [41]
Meningitis long-term sequelae (children) 0.269 [41]
Meningitis long-term sequelae (adult) 0.286 [41]
Bacteremia long-term sequelae (children) 0.269 Assumed to be the same as meningitis
Short-term Disutility weight Reference/assumptions
AOM, acute otitis media.
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weights, as shown in Table 3, which had been used in other
published PHiD-CV cost-effectiveness analyses, were used in the
current analyses [12,39,40].Resource Use and Costs
The cost analyses were conducted from the perspective of the
Philippine government. Only direct medical costs (e.g., hospital-
ization, inpatient/outpatient diagnostic tests and procedures,
medication/vaccine costs, and health care professionals’ fees)
were included. In the model, we have conservatively applied the
same price of 800 pesos (US $1 ¼ 42.13 pesos in 2012) per vaccine
dose for both PHiD-CV and PCV13. The 800 pesos per vaccine dose
price was derived from the indicative tendering offer price of
GlaxoSmithKline for PHiD-CV in the Philippines. Cost data for
acute episodes and related long-term sequelae of the IPD andTable 4 – Costs for pneumococcal diseases.
Pneumococcal disease Average
costs (PHP)*
Meningitis—ﬁrst year (acute episode) 97,000 Expe
la
Meningitis long-term sequelae annual cost
for subsequent years
23,500 Expe
la
Bacteremia—hospitalized (acute episode) 67,000 Expe
m
Bacteremia—outpatient (acute episode) 6,000 Expe
an
Bacteremia long-term sequelae annual cost
for subsequent years
11,750
(children)
Expe
m
18,170 (adult)
Pneumonia—hospitalized (acute episode) 23,500 Expe
an
Pneumonia—outpatient (acute episode) 1,300 Expe
AOM hospitalized myringotomy 4,500 Expe
an
AOM GP consultations (acute episode) 743 [42]
AOM, acute otitis media; GP, general practitioner; IV, intravenous; PHP,
* US $1 ¼ 42.13 pesos.CAP (Table 4) were based on expert validation of clinical treat-
ment pathways and an average of the public and private
hospitals costs. AOM costs were based on locally published data
[42]. Only direct medical costs were counted in the study. Health
effects and costs were both discounted at 5% per annum.Sensitivity Analyses
For both comparisons, extensive one-way sensitivity analyses
were performed to evaluate how robust the results are to the
change in model variables. These were performed using 20%
(up to 50% depending on the inputs) for each of the base-case
value of most of the variables; the upper and lower limits of the
95% conﬁdence interval were used for vaccine efﬁcacy inputs. We
also tested the effect of assuming the same steady herd effect of
30% for the cohort on year 11 and beyond because we assumed
that the protection of both these vaccines lasts for 10 years. ForReference
rts’ validated calculation, including room charge, medication, IV,
boratory tests, and physician’s fee
rts’ validated calculation, including room charge, medication, IV,
boratory tests, and physician’s fee
rts’ validated calculation, including room charge, laboratory tests,
edication, and physician’s fees
rts’ validated calculation, including consultation, laboratory tests,
d medication
rts’ validated calculation, including room charge, laboratory tests,
edication, and physician’s fees
rts’ validated calculation, including consultation, laboratory tests,
d medication
rts’ opinions based on PhilHealth 2011 [49]
rts’ validated calculation, including consultation fee, medication,
d chest X-ray fees
Philippine pesos.
Table 5 – Estimated effect of PHiD-CV and PCV13 on lifetime disease burden (projected number of cases) in the
Philippines.
Health
outcomes
No-
vaccination
program (A)
PCV13 2 þ 1
vaccination
program (B)
PHiD-CV 2 þ 1
vaccination
program (C)
Difference PHiD-CV vs.
no-vaccination program
(C  A)
Difference
PHiD-CV vs.
PCV13 (C  B)
IPD cases (acute
episode)
11,919 10,768 10,818 1,102 50
All-cause
pneumonia cases
(acute episode)
2,342,129 2,277,482 2,277,466 64,664 16
AOM cases (acute
episode)
3,691,038 3,510,803 3,383,123 261,096 127,680
IPD cases (long-
term sequelae)
3,378 3,299 3,302 75 3
All deaths 39,574 1,773,057 1773,057 3,343 0
AOM, acute otitis media; IPD, invasive pneumococcal disease; PCV13, pneumococcal 13-valent conjugate vaccine; PHiD-CV, pneumococcal
polysaccharide nontypeable Haemophilus inﬂuenzae protein D conjugate vaccine.
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scenario analyses were performed with1.T
C
V
c
A
L
T
(u
T
c
T
Q
In
c
e
ra
A
p
*different price of PCV13;
2. unpublished local AOM etiology with a high proportion of
NTHi-attributed AOM versus S. pneumonia–attributed AOM as
compared with the internationally published data; and3. inclusion of AOM long-term sequelae and complications.
We also conducted probabilistic sensitivity analysis to assess
the overall effect on results from simultaneous uncertainties
around input parameters, and present the results in a cost-
effectiveness plane. Point estimates used in the base case asable 6 – Direct costs by disease and vaccination progra
ost category No-
vaccination
program (A)
PCV13 2 þ 1
vaccination
program (B)
PH
v
p
accination
osts
0 4,331,835,868 4
cute episode
IPD 903,957,346 804,351,625 8
All-cause
pneumonia
13,432,362,973 12,304,532,946 12
AOM 3,145,091,640 3,031,573,906 2
ong-term
sequelae
IPD 2,835,267,365 2,643,669,639 2
otal
ndiscounted)
20,316,679,324 23,115,963,985 23
otal discounted
osts
10,273,482,597 13,219,953,924 13
otal discounted
ALYs gained
31,268,126 31,323,884
cremental
ost-
ffectiveness
tio
OM, acute otitis media; IPD, invasive pneumococcal disease; PCV13, p
olysaccharide nontypeable Haemophilus inﬂuenzae protein D conjugate v
US $1 ¼ 42.13 pesos.input data were replaced by appropriate choice of distributions,
for example, lognormal distribution for efﬁcacy parameters,
triangular distribution for cost inputs, and beta distribution for
disutility weights.Results
Predicted Effect of Vaccination on Disease Burden and Costs
For the projected birth cohort of 1,812,137 in the Philippines in
2012, it was estimated that without a UMV there would be a total
of 11,919 cases of IPD (3,513 cases of meningitis and 8,406 cases ofm in the Philippines (2012 Philippine pesos*).
iD-CV 2 þ 1
accination
rogram (C)
Difference PHiD-CV vs.
no-vaccination
program
(C  A)
Difference
PHiD-CV vs.
PCV13
(C  B)
,331,835,868 4,331,835,868 0
08,699,878 95,257,468 4,238,253
,304,464,588 1,127,898,385 68,358
,917,838,591 227,253,049 113,735,315
,652,113,618 183,153,747 8,443,979
,014,952,543 2,698,273,219  101,011,442
,127,492,075 2,854,009,477 92,461,849
31,324,182 56,056 298
50,913 Dominant
neumococcal 13-valent conjugate vaccine; PHiD-CV, pneumococcal
accine; QALY, quality-adjusted life-year.
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cases of all-cause pneumonia, and 3,691,038 cases of AOM over
their lifetime under the current standard of care for pneumo-
coccal diseases (Appendix Table 7 in Supplemental Materials
found at http://dx.doi.org/10.1016/j.vhri.2014.04.004). The associ-
ated economic burden (discounted) amounted to be 10,273.48
million pesos. For the base-case scenario, it was found that UMV
with PHiD-CV 2 þ 1 was highly cost-effective as compared with
the no- vaccination strategy for the 2012 birth cohort (n ¼
1,812,137), with an ICER of 50,913 peso/QALY gained, which is
less than one time the GDP per capita of the Philippines as
recommended by the WHO (equivalent to 103,366 pesos). In
another comparison using the same cohort, it was projected that
compared with PCV13, PHiD-CV 2 þ 1 would have a substantially
greater reduction in the AOM cases (127,680 cases) and compa-
rable reduction in IPD and CAP-related cases and IPD long-term
sequelae (Table 5). Both vaccines would provide a broadly similar
effect on reduction in the number of IPD-related and CAP-related
deaths in the Philippines. The estimated ﬁnancial projections
based on the same analysis showed that the PHiD-CV 2 þ 1
vaccination program can reduce the ﬁnancial burden of IPD, CAP,
and AOM of the 2012 birth cohort (n ¼ 1,812,137) over lifetime
(Table 6) by approximately 1.54 billion pesos against no vacci-
nation. In comparison against the PCV13 vaccination program,
the PHiD-CV vaccination program was estimated to result in total
savings of approximately 92.5 million pesos while having an
additional gain of 298 QALYs, meaning 298 additional years in the
perfect health state. Therefore, the PHiD-CV 2 þ 1 vaccination
program was evaluated to be a cost-saving and dominant
strategy as compared with the PCV13 2 þ 1 vaccination program
for the Philippines. This was indeed a conservative estimation
without taking into account the complications and long-term
sequelae associated with AOM. If the complications andFig. 2 – Tornado diagram for the top 10 most inﬂuential parame
vaccination program versus no vaccination (one-way sensitivity
conﬁdence interval; CAP, community-acquired pneumonia; GP,
inﬂuenzae; PHiD-CV, pneumococcal polysaccharide nontypeablelong-term sequelae were incorporated into the base-case sce-
nario, the total savings of PHiD-CV 2 þ 1 as compared with PCV13
would be around 267 million pesos, with a higher QALY gained
of 364.Sensitivity Analyses
The tornado diagram in Figure. 2 shows the effect of the 10 most
inﬂuential input parameters around the base-case value on the
discounted ICER (descending order), based on the extensive one-
way sensitivity analyses. It was found that most of the model
variables had very little inﬂuence over the conclusion that the PHiD-
CV 2 þ 1 vaccination program as compared with the no-vaccination
strategy was a highly cost-effective strategy for the Philippines.
Among all the variables, only one variable (% reduction in CAP
hospitalizations) had a greater effect on the ﬁnal conclusion. When
the lower limit of the 95% conﬁdence interval was selected, the ICER
was increased to 151,012 pesos/QALY gained, less than three times
the GDP per capita of the Philippines (equivalent to 310,098 pesos).
As expected, PHiD-CV 2 þ 1 became even more cost-effective than
the no-vaccination strategy when a herd effect of 30% was
assumed, resulting in a lower ICER of 46,568 pesos/QALY.
The presentation of a one-way sensitivity analysis for a
dominant base case can be difﬁcult to interpret using a tradi-
tional tornado diagram because of the inability to calculate an
ICER. Therefore, Figure. 3 presents the effect of the nine most
inﬂuential variables on a cost-effectiveness plane generated by
comparing the PhiD-CV 2 þ 1 vaccination program with the
PCV13 2 þ 1 vaccination program in the Philippines. It was found
that most of the model variables had little inﬂuence over the
cost-saving conclusion of the PhiD-CV 2 þ 1 vaccination program.
As seen in Figure. 3, there are two variables/assumptions chang-
ing the conclusion. These two observations, however, are notters of the cost-effectiveness analysis of PHiD-CV 2 þ 1
analysis) in the Philippines. AOM, acute otitis media; CI,
general practitioner; NTHi, nontypeable Haemophilus
Haemophilus inﬂuenzae protein D conjugate vaccine.
Fig. 3 – Univariate sensitivity analysis comparing PHiD-CV with PCV13 in the Philippines. The effect of the nine most
inﬂuential variables on cost-effectiveness results of the PHiD-CV 2 þ 1 vaccination program versus the PCV13 2 þ 1 strategy.
AOM, acute otitis media; CI, conﬁdence interval; GP, general practitioner; LL, lower limit; NTHi, nontypeable Haemophilus
inﬂuenzae; PCV13, pneumococcal 13-valent conjugate vaccine; PHiD-CV, pneumococcal polysaccharide nontypeable
Haemophilus inﬂuenzae protein D conjugate vaccine; QALY, quality-adjusted life-year; UL, upper limit.
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Fig. 4 – Cost-effectiveness plane of probabilistic sensitivity
analysis comparing PHiD-CV 2 þ 1 with the no-vaccination
strategy in the Philippines. PHiD-CV, pneumococcal
polysaccharide nontypeable Haemophilus inﬂuenzae protein D
conjugate vaccine; QALY, quality-adjusted life-year.
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to the lower limit of the 95% conﬁdence interval for PCV7
for IPD, it was expected that fewer IPD cases could be prevented,
resulting in a lower gain in QALY of the PhiD-CV strategy
although the overall costs were still lower with PhiD-CV due to
the substantial savings by the prevention of AOM cases. Second,
when the percentage of AOM cases due to S. pneumonia and
NTHi was adjusted from 25.7% and 32.3% to 56% and 22%,
respectively, the result showed less favorable QALYs of PhiD-CV
with lower cost savings compared with PCV13. This change
was in line with the key difference between the two vaccines
that PhiD-CV provides better protection against AOM caused by
NTHi. However, as anticipated, the herd effect of 30% assumed
for both vaccines did not alter the ICER result in the base-case
analysis.
In addition, an alternative scenario analysis showed that if
the price of PCV13 per dose was increased from 800 pesos to 900
pesos, the discounted ﬁnancial savings of PhiD-CV versus PCV13
would be signiﬁcantly increased to close to 620.34 million pesos
because of the substantial increase in the vaccination costs.
Another scenario analysis was also performed with the
unpublished local etiology data (2012) from Dr. Gretchen
Navarro-Locsin on AOM cultures collected from Philippine Gen-
eral Hospital, Philippine Children’s Medical Centre, and St. Luke’s
Medical Centre, with the NTHi-attributed AOM of 52.9% and S.
pneumonia–attributed AOM of 23.5% (the base-case assumptions
based on published data were as follows: NTHi-attributed AOM:
32.3%; S. pneumonia–attributed AOM: 35.9%) [43]. The results
showed that as compared with PCV13, PhiD-CV would save
162.1 million pesos, with incremental QALYs gained of 739.The third scenario analysis showed that if the AOM long-term
sequelae and complications were counted into the analysis, the
total savings would be close to 267 million pesos, with incre-
mental QALYs gained of 364.
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Fig. 5 – Cost-effectiveness plane of probabilistic sensitivity
analysis comparing PHiD-CV 2 þ 1 with no PCV13 2 þ 1 in
the Philippines. PCV13, pneumococcal 13-valent conjugate
vaccine; PHiD-CV, pneumococcal polysaccharide
nontypeable Haemophilus inﬂuenzae protein D conjugate
vaccine’ QALY, quality-adjusted life-year.
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tions fell below the three times the GDP per capita threshold,
indicating a high level of certainty that the PHiD-CV vaccination
program is cost-effective compared with the no-vaccination
strategy (Fig. 4). In comparison against the PCV-13 vaccination
program, the PHiD-CV strategy was estimated to be very likely a
dominant strategy (74.2% of the simulations located in the south-
east quadrant in Fig. 5: additional QALY gains with cost savings).Discussion
Globally, pneumococcal and NTHi-associated diseases continue
to result in substantial direct medical and caregiver costs despite
current PCV7 vaccination programs [43]. The evaluation shows
substantial health and economic burden of pneumococcal dis-
eases on the health care system over the lifetime of the birth
cohort without pediatric vaccination program against pneumo-
coccal diseases. For the projected birth cohort of 1,812,137 new-
borns in the Philippines in 2012, there would be a total of 11,919
cases of IPD (3,513 cases of meningitis and 8,406 cases of
bacteremia), with 3,378 cases with long-term sequelae, 2,342,129
cases of all-cause pneumonia, and 3,691,038 cases of AOM over
their lifetime under the current standard of care for pneumo-
coccal diseases without a UMV program in the Philippines. The
associated economic burden (discounted) amounted to 10,273.48
million pesos.
If the government were to adopt the PHiD-CV (2 þ 1 schedule)
vaccination program as compared with the no-vaccination strat-
egy, potentially 3,343 deaths due to IPD and CAP and 326,862
cases of pneumococcal diseases (1,102 IPD cases, 64,664 pneumo-
nia cases, and 261,096 AOM cases) would be prevented over the
lifetime horizon of the study cohort. The cost-effectiveness
analysis also shows that the discounted ICER of the PHiD-CV 2
þ 1 vaccination versus the no-vaccination program was 50,913
peso/QALY gained, which is considered to be cost-effective
because it is less than one time the GDP per capita of the
Philippines.
When the PHiD-CV (2 þ 1) vaccination program is compared
with the PCV13 (2 þ 1) strategy, the results show that an addi-
tional 127,646 cases would be prevented with a reduction in AOMcases due to NTHi AOM and a comparable reduction in IPD and
CAP-related cases. This would further result in substantial
ﬁnancial savings of 92.5 million pesos with higher QALYs gained
(298 additional years in perfect health state). Therefore, the study
shows that PHiD-CV is a cost-saving and dominant strategy as
compared with PCV13. It is also interesting to note that although
the incremental QALYs gained of 298 for the entire cohort over
lifetime appear to be small, this improvement actually reﬂects
signiﬁcant disease burden reduction in AOM (n ¼ 127,680 cases)
of PHiD-CV versus PCV13 because the disutility per episode we
assumed in the data input for the AOM acute cases was quite
minimal (disutility of AOM ¼ 0.005).
Our ﬁndings are in line with those of the other published cost-
effectiveness analysis to compare PHiD-CV vaccination programs
with PCV13. By et al. [9] used a Markov cohort model to compare
the PHiD-CV 2 þ 1 strategy versus the PCV13 2 þ 1 strategy in
Sweden from a societal perspective. It was found that the PHiD-
CV strategy would generate an additional 45.3 QALYs with a
substantial savings of estimated 62 million Swedish kroner (close
to US $9.3 million) for a cohort of 112,120 children [9]. Robberstad
et al. [10] have also applied a Markov model to evaluate the cost-
effectiveness of pneumococcal conjugate vaccines (PCV7, PCV13,
and PHiD-CV) for a speciﬁc birth cohort (n ¼ 61,152) in Norway;
PHiD-CV was also found to be a dominant strategy as compared
with PCV13 with substantial savings of 24 million Norwegian
krone (close to US $4.15 million), with an additional 49 QALYs
gained [10]. In the study published by Knerer et al. [12], it was
found that PHiD-CV was also a dominant strategy as compared
with PCV13, offering an additional savings of Can $9 million
(close to US $9.2 million) in the birth cohort size of approximately
33 million newborns in Canada, and additional savings of £4.9
million (close to US $7.2 million) in the United Kingdom with the
birth cohort size of approximately 61 million newborns [15].
It is important to note that a conservative approach was
adopted in the base-case scenario analysis. It was assumed that
PHiD-CV possessed an efﬁcacy against NTHi-derived AOM, but
not on IPD or CAP, the inclusion of which would result in higher
ﬁnancial savings with higher QALYs gained as compared with
PCV13. The AOM-associated complications and long-term seque-
lae were also not included in the base-case scenario. As men-
tioned in the Results section, if AOM complications and long-
term sequelae were included on the basis of local data reported
by Marcelo [Case Series Report on Otogenic Complications of
Chronic OM. Philippines Children's Medical Center, unpublished
data, 2004], the total savings of PHiD-CV compared with PCV13
would be close to 267 million pesos, with a higher QALY gained of
364 [9]. On a separate note, we believe that more total cost
savings would be estimated if the analysis was conducted from a
societal perspective in which there is less productivity loss of
parents or caregivers for taking care of children suffering from
AOM for UMV with PHiD-CV. Similarly, the same trend of
analyses would be observed if costs for other related expenses,
for example, transport to and return from the hospitals and
clinics, were included.
As is the case with all the modeling exercises, there are a
number of limitations to the current analysis as well. First,
ideally, a dynamic model should be considered for the evalua-
tions of vaccination against infectious diseases. In the absence of
reliable and published data required for constructing a dynamic
model, however, an established Markov model for vaccination
against pneumococcal diseases was used. Given that recent data
tend to suggest a similar herd effect between the two vaccines
[44–46], we believe that the study analyses and ﬁndings would
not likely be much different from those reported in the article
should a dynamic model be developed and used in this study.
This assumption, however, may be changed with the availability
of newer data. In this analysis, best locally published data were
V A L U E I N H E A L T H R E G I O N A L I S S U E S 3 C ( 2 0 1 4 ) 1 5 6 – 1 6 6 165used wherever available, yet there were still some speciﬁc clinical
epidemiology variables that were not available locally. Similarly,
local utility data, ideally, should be used in the analyses. As
always, it is not available in many developing countries including
the Philippines. So, published disutility weights have been con-
sidered and used. Given that the relatively small values of the
disutility weights applied and also the relatively short episode of
each of the infections included, we believe that the effect of
disutility weights on QALY and hence cost-effectiveness ratios is
negligible. Furthermore, only a small proportion of patients was
assumed to have long-term disease sequelae and differences
between these proportions were small between the two vacci-
nated groups. Published data or regionally available data sets
were therefore reviewed by local clinical experts, and reasonable
adjustments were made from these.Conclusions
This economic modeling study showed that a PHiD-CV 2 þ 1
universal vaccination program could potentially prevent a sub-
stantial number of deaths and cases of pneumococcal diseases as
compared with the no-vaccination strategy. The results also
suggested that the PHiD-CV 2 þ 1 vaccination program is likely
to be a cost-effective strategy and could potentially provide
savings with higher health gain measured in QALYs as compared
with the PCV13 2 þ 1 strategy. Monetary estimates based on
Markov cohort analyses could be used to assess the return on
investment from vaccination programs of the national govern-
ment and they could be considered in policy making.Acknowledgments
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